DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma

Gynecologic Oncology

Volumn 111, Issue 2, 2008, Pages 320-329

  Feng, Qinghua ^a   Deftereos, Georgios ^a   Hawes, Stephen E ^b   Stern, Joshua E ^a   Willner, Julia B ^d   Swisher, Elizabeth M ^a   Xi, Longfu ^a   Drescher, Charles ^c   Urban, Nicole ^c   Kiviat, Nancy ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c USA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Her 2 neu overexpression; Hypermethylation; Ovarian cancer; p53

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; PROTEIN P53;

ADULT; ARTICLE; BENIGN TUMOR; CABIN1 ONCOGENE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER TISSUE; CDH13 ONCOGENE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HIC1 ONCOGENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MINT31 ONCOGENE; ONCOGENE; ONCOGENE NEU; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RASSF1 ONCOGENE; TREATMENT RESPONSE;

ADULT; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENES, ERBB-2; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTATION; NEOPLASM STAGING; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 55649100076     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.07.036     Document Type: Article

References (54)

1. Holschneider C.H., and Berek J.S. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin. Surg. Oncol. 19 (2000) 3-10
2. Herman J.G., and Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349 (2003) 2042-2054
3. Boyd J., and Rubin S.C. Hereditary ovarian cancer: molecular genetics and clinical implications. Gynecol. Oncol. 64 (1997) 196-206
4. Fraser M., Leung B., Jahani-Asl A., Yan X., Thompson W.E., and Tsang B.K. Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod. Biol. Endocrinol 1 (2003) 66
5. Yoon J.H., Dammann R., and Pfeifer G.P. Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int. J. Cancer 94 (2001) 212-217
6. Fu Y., Campbell E.J., Shepherd T.G., and Nachtigal M.W. Epigenetic regulation of proprotein convertase PACE4 gene expression in human ovarian cancer cells. Mol. Cancer Res. 1 (2003) 569-576
7. Sellar G.C., Watt K.P., Rabiasz G.J., Stronach E.A., Li L., Miller E.P., et al. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat. Genet 34 (2003) 337-343
8. Terasawa K., Sagae S., Toyota M., Tsukada K., Ogi K., Satoh A., et al. Epigenetic inactivation of TMS1/ASC in ovarian cancer. Clin. Cancer Res. 10 (2004) 2000-2006
9. Takada T., Yagi Y., Maekita T., Imura M., Nakagawa S., Tsao S.W., et al. Methylation-associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers. Cancer Sci. 95 (2004) 741-744
10. Wiley A., Katsaros D., Fracchioli S., and Yu H. Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. Int. J. Gynecol. Cancer 16 (2006) 210-218
11. Wang Z., Li M., Lu S., Zhang Y., and Wang H. Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway. Cancer Biol. Ther. 5 (2006) 256-260
12. Toyooka S., Tokumo M., Shigematsu H., Matsuo K., Asano H., Tomii K., et al. Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. Cancer Res. 66 (2006) 1371-1375
13. Fiegl H., Millinger S., Goebel G., Muller-Holzner E., Marth C., Laird P.W., et al. Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res. 66 (2006) 29-33
14. Weisenberger D.J., Siegmund K.D., Campan M., Young J., Long T.I., Faasse M.A., et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet 38 (2006) 787-793
15. Strathdee G., Appleton K., Illand M., Millan D.W., Sargent J., Paul J., et al. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am. J. Pathol. 158 (2001) 1121-1127
16. Dhillon V.S., Young A.R., Husain S.A., and Aslam M. Promoter hypermethylation of MGMT, CDH1, RAR-beta and SYK tumour suppressor genes in granulosa cell tumours (GCTs) of ovarian origin. Br. J. Cancer 90 (2004) 874-881
17. Takeuchi T., Liang S.B., Matsuyoshi N., Zhou S., Miyachi Y., Sonobe H., et al. Loss of T-cadherin (CDH13, H-cadherin) expression in cutaneous squamous cell carcinoma. Lab. Invest. 82 (2002) 1023-1029
18. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 9821-9826
19. Yuan Y., Mendez R., Sahin A., and Dai J.L. Hypermethylation leads to silencing of the SYK gene in human breast cancer. Cancer Res. 61 (2001) 5558-5561
20. Rathi A., Virmani A.K., Schorge J.O., Elias K.J., Maruyama R., Minna J.D., et al. Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin. Cancer Res. 8 (2002) 3324-3331
21. Dong S.M., Kim H.S., Rha S.H., and Sidransky D. Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin. Cancer Res. 7 (2001) 1982-1986
22. Hattori M., Sakamoto H., Satoh K., and Yamamoto T. DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes. Cancer Lett. 169 (2001) 155-164
23. Esteller M., Corn P.G., Urena J.M., Gabrielson E., Baylin S.B., and Herman J.G. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res. 58 (1998) 4515-4518
24. Du Y., Carling T., Fang W., Piao Z., Sheu J.C., and Huang S. Hypermethylation in human cancers of the RIZ1 tumor suppressor gene, a member of a histone/protein methyltransferase superfamily. Cancer Res. 61 (2001) 8094-8099
25. Wei S.H., Chen C.M., Strathdee G., Harnsomburana J., Shyu C.R., Rahmatpanah F., et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin. Cancer Res. 8 (2002) 2246-2252
26. Tobias E.S., Hurlstone A.F., MacKenzie E., McFarlane R., and Black D.M. The TES gene at 7q31.1 is methylated in tumours and encodes a novel growth-suppressing LIM domain protein. Oncogene 20 (2001) 2844-2853
27. O'Doherty A.M., Church S.W., Russell S.E., Nelson J., and Hickey I. Methylation status of oestrogen receptor-alpha gene promoter sequences in human ovarian epithelial cell lines. Br. J. Cancer 86 (2002) 282-284
28. Feng Q., Balasubramanian A., Hawes S.E., Toure P., Sow P.S., Dem A., et al. Detection of hypermethylated genes in women with and without cervical neoplasia. J. Natl. Cancer Inst. 97 (2005) 273-282
29. Swisher E.M., Wollan M., Mahtani S.M., Willner J.B., Garcia R., Goff B.A., et al. Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. Am. J. Obstet. Gynecol. 193 (2005) 662-667
30. Storey J.D. A direct approach to false discovery rates. J. R. Stat. Soc., Ser. B Stat. Methodol. 64 (2002) 479-498
31. Ludbrook J. Multiple inferences using confidence intervals. Clinical and Experimental Pharmacology and Physiology 27 (2000) 212-215
32. McCullach P., and Nelder J. Generalized linear models (1989), Chapman & Hall, London, United Kingdom
33. Agathanggelou A., Honorio S., Macartney D.P., Martinez A., Dallol A., Rader J., et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 20 (2001) 1509-1518
34. Ibanez de Caceres I., Battagli C., Esteller M., Herman J.G., Dulaimi E., Edelson M.I., et al. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res. 64 (2004) 6476-6481
35. Makarla P.B., Saboorian M.H., Ashfaq R., Toyooka K.O., Toyooka S., Minna J.D., et al. Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin. Cancer Res. 11 (2005) 5365-5369
36. Teodoridis J.M., Hall J., Marsh S., Kannall H.D., Smyth C., Curto J., et al. CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res. 65 (2005) 8961-8967
37. Yuecheng Y., Hongmei L., and Xiaoyan X. Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin. Exp. Metastasis. 23 (2006) 65-74
38. Strathdee G., Vass J.K., Oien K.A., Siddiqui N., Curto-Garcia J., and Brown R. Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. Gynecol. Oncol. 97 (2005) 898-903
39. Yang H.J., Liu V.W., Wang Y., Tsang P.C., and Ngan H.Y. Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC. Cancer 6 (2006) 212
40. Wiley A., Katsaros D., Chen H., Rigault de la Longrais I.A., Beeghly A., Puopolo M., et al. Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 107 (2006) 299-308
41. Wei S.H., Balch C., Paik H.H., Kim Y.S., Baldwin R.L., Liyanarachchi S., et al. Prognostic DNA methylation biomarkers in ovarian cancer. Clin. Cancer Res. 12 (2006) 2788-2794
42. Esteller M., Silva J.M., Dominguez G., Bonilla F., Matias-Guiu X., Lerma E., et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst. 92 (2000) 564-569
43. Sutherland K.D., Lindeman G.J., Choong D.Y., Wittlin S., Brentzell L., Phillips W., et al. Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene 23 (2004) 7726-7733
44. Kamikihara T., Arima T., Kato K., Matsuda T., Kato H., Douchi T., et al. Epigenetic silencing of the imprinted gene ZAC by DNA methylation is an early event in the progression of human ovarian cancer. Int. J. Cancer (2005)
45. Tam K.F., Liu V.W., Liu S.S., Tsang P.C., Cheung A.N., Yip A.M., et al. Methylation profile in benign, borderline and malignant ovarian tumors. J. Cancer Res. Clin. Oncol (2006)
46. Gifford G., Paul J., Vasey P.A., Kaye S.B., and Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin. Cancer Res. 10 (2004) 4420-4426
47. Katsaros D., Cho W., Singal R., Fracchioli S., Rigault De La Longrais I.A., Arisio R., et al. Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecol. Oncol. 94 (2004) 685-692
48. Chiang J.W., Karlan B.Y., Cass L., and Baldwin R.L. BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. Gynecol. Oncol. 101 (2006) 403-410
49. Shames D.S., Minna J.D., and Gazdar A.F. Methods for detecting DNA methylation in tumors: from bench to bedside. Cancer. Lett. (2006)
50. Jeronimo C., Usadel H., Henrique R., Silva C., Oliveira J., Lopes C., et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 60 (2002) 1131-1135
51. Brown T.J., Shaw P.A., Karp X., Huynh M.H., Begley H., and Ringuette M.J. Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer. Gynecol. Oncol. 75 (1999) 25-33
52. Klimp A.H., Hollema H., Kempinga C., van der Zee A.G., de Vries E.G., and Daemen T. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res. 61 (2001) 7305-7309
53. Tuhkanen H., Anttila M., Kosma V.M., Heinonen S., Juhola M., Helisalmi S., et al. Frequent gene dosage alterations in stromal cells of epithelial ovarian carcinomas. Int. J. Cancer 119 (2006) 1345-1353
54. Tuhkanen H., Anttila M., Kosma V.M., Yla-Herttuala S., Heinonen S., Kuronen A., et al. Genetic alterations in the peritumoral stromal cells of malignant and borderline epithelial ovarian tumors as indicated by allelic imbalance on chromosome 3p. Int. J. Cancer 109 (2004) 247-252